Clinical trials
Pulmonary Hypertension Associated With HFpEF clinical trials
Below are recruiting pulmonary hypertension associated with hfpef clinical trials, each written for real people, not researchers. We’re tracking 9 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07662655RecruitingEarly Phase 1
PADN for pulmonary hypertension after mitral valve repair
This study tests a new procedure called pulmonary artery denervation (PADN) to lower high blood pressure in the lungs that persists after a mitral valve repair. It aims to see if this extra treatment improves symptoms and outcomes for people with this condition.
Xiamen, FujianAges 18–80 - NCT07436689Enrolling by invitationPhase 3
Long-term study of oral levosimendan for heart failure
This long-term study gives continued access to the oral levosimendan medication for people who finished the earlier TNX-103 study. The goal is to see if ongoing treatment remains safe and helpful.
Chicago, IllinoisAges Any age - NCT07359599RecruitingPhase 4
IV iron for exercise and quality of life in pulmonary hypertension
This study tests whether intravenous (IV) iron can help people with pulmonary hypertension feel better, have more energy, and enjoy a better quality of life. You may qualify if you have a type of pulmonary hypertension and low iron levels.
AalstAges 18 years+ - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT07179380RecruitingPhase 3
Inhaled treprostinil for pulmonary hypertension related to interstitial lung disease
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
Phoenix, ArizonaAges 18 years+ - NCT07147114RecruitingPhase 4
Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
BusanAges 19 years+ - NCT04555161Recruiting
Test of an implanted device for pulmonary arterial hypertension
This trial studies an implanted system (the Aria CV Pulmonary Hypertension System) to treat pulmonary arterial hypertension, a serious lung-blood vessel and heart condition. It aims to see whether the device can improve outcomes for people who are still sick despite existing PH medicines.
La Jolla, CaliforniaAges 18 years+ - NCT07123779RecruitingPhase 1/Phase 2
Study of a new drug for heart failure with pulmonary hypertension
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
Kansas City, MissouriAges 18 years+ - NCT04062565RecruitingPhase 3
Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Tucson, ArizonaAges 18 years+
Hear when a new Pulmonary Hypertension Associated With HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary hypertension associated with hfpef?
- Yes. Clin2 currently lists 9 recruiting pulmonary hypertension associated with hfpef studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary hypertension associated with hfpef trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary hypertension associated with hfpef trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Artery Hypertension
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Pulmonary Hypertension (Diagnosis)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.